March-In Rights: The Dormant Nuclear Option That Could Reshape Drug Pricing and Pharma IP
The Bayh-Dole Act of 1980 is arguably the single most consequential piece of legislation in the history of American biomedical […]
Generic Drug Portfolio Strategy: 7 Signs Your Playbook Is Killing Your Margins
The Hatch-Waxman Act was supposed to make generic pharmaceuticals a reliable business. File an Abbreviated New Drug Application (ANDA), prove
Generic Drug Portfolio Strategy: 7 Signs Your Playbook Is Killing Your Margins Read Post »
Drug Patent Myths Debunked: The Definitive IP Strategy Guide for Pharma Analysts
The ‘grand bargain’ of pharmaceutical patents is one of the most consequential, most contested, and most misunderstood arrangements in modern
Drug Patent Myths Debunked: The Definitive IP Strategy Guide for Pharma Analysts Read Post »
India vs. China Pharma: Who Wins the $300 Billion Supply Chain War?
The rivalry between India and China in pharmaceuticals is the most consequential industrial contest of the next decade. It will
India vs. China Pharma: Who Wins the $300 Billion Supply Chain War? Read Post »
Pharmaceutical Patent Litigation: The Complete Strategic Playbook for IP Teams and Portfolio Managers
Patent litigation is where drug revenue is won or lost. For a blockbuster product generating $5 billion annually, a single
Drug Patent Cliff Modeling: The Complete Quantitative Playbook for Pharma Analysts
Every five years or so, the pharmaceutical industry rediscovers the patent cliff as though it is a new emergency. It
Drug Patent Cliff Modeling: The Complete Quantitative Playbook for Pharma Analysts Read Post »
Pharma Patent Mastery: 18 Terms That Decide Who Wins the Drug Market
Every major pharmaceutical revenue event, from a blockbuster’s first generic competitor to a biosimilar’s delayed U.S. launch, traces back to
Pharma Patent Mastery: 18 Terms That Decide Who Wins the Drug Market Read Post »
180-Day Generic Exclusivity: The Complete Paragraph IV Playbook for Maximum First-Mover Profit
The single most valuable regulatory asset in the U.S. generic pharmaceutical industry is not a patent. It is the absence
Drug Patent Data: The Institutional Investor’s Complete Playbook for Pharma Alpha
Part I: The Architecture of Pharmaceutical Value — Patents as Financial Instruments What a Drug Patent Actually Is (And What
Drug Patent Data: The Institutional Investor’s Complete Playbook for Pharma Alpha Read Post »
